Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - Taylor & Francis
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
被引用次数：111 相关文章
[PDF] researchgate.net

[PDF][PDF] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

JCH Soo, R Gucalp, B Halmos, A Lara Wang… - Future Oncol, 2018 - researchgate.net
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study

MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - einstein.elsevierpure.com
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study

MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - pure.lib.cgu.edu.tw
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - dirros.openscience.si
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

MJ Hochmair, A Morabito, D Hao, Y Cheng-Ta… - Future …, 2018 - search.proquest.com
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

MJ Hochmair, A Morabito, D Hao, CT Yang, RA Soo… - Future Oncology, 2018 - cir.nii.ac.jp
抄録< jats: p> Aim: To assess outcomes in patients with EGFR mutation-positive (Del19,
L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real …
[PDF] academia.edu

[PDF][PDF] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

JCH Soo, R Gucalp, B Halmos, A Lara Wang… - Future Oncol, 2018 - academia.edu
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

MJ Hochmair, A Morabito, D Hao… - Future oncology …, 2018 - pubmed.ncbi.nlm.nih.gov
Aim To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

MJ Hochmair, A Morabito, D Hao, CT Yang… - Future Oncology …, 2018 - europepmc.org
Aim To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …